Company: SION
Filing Date: 2025-01-17
Form Type: S-1
Source: 0001193125-25-008474
Chunk: 270

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-01-17
Form: S-1
Chunk 270
---
.B.A.

In March 2022, we entered into a board of directors agreement with Paul Clancy (the “Clancy Agreement”) pursuant to which Mr. Clancy serves as
the independent chairman of our board of directors, effective as of June 6, 2022. Under the Clancy Agreement, Mr. Clancy was entitled to receive an initial equity grant consisting of an option to purchase 175,000 shares of common stock,
which vests over a four-year period in 16 equal quarterly installments following June 6, 2022, subject to Mr. Clancy’s continued service with us through each applicable vesting date. In addition, under the Clancy Agreement, Mr. Clancy
is entitled to an annual cash retainer of $50,000, payable quarterly, as well as reimbursement for reasonable travel expenses incurred by Mr. Clancy for his attendance at meetings of our board of directors.

In March 2024, following the Series C Financing, our board of directors granted Mr. Clancy a non-qualified
stock option to purchase 96,014 shares of common stock, which vests in 48 equal monthly installments over a period of four years following March 4, 2024, subject to Mr. Clancy’s continued service with us through each applicable vesting
date.

Laurie Stelzer

On November 12, 2024, we
entered into a board of directors agreement with Laurie Stelzer (the “Stelzer Agreement”) pursuant to which Ms. Stelzer serves as a director and chair of the audit committee, effective as of November 14, 2024. In accordance with the
Stelzer Agreement in November 2024, Ms. Stelzer was granted an initial equity grant consisting of an option to purchase 64,991 shares of common stock, which vests in equal annual installments over a three-year period following November 14,
2024, subject to Ms. Stelzer’s continued service with us through each applicable vesting date. In addition, Ms. Stelzer is entitled to an annual cash retainer of $40,000 for her role as a director, as well as reimbursement for
reasonable travel expenses incurred by Ms. Stelzer for her attendance at meetings of our board of directors, and, contingent upon the consummation of this offering, consistent with the terms of the non-employee director compensation policy, $16,000
for her role as the chair of the audit